Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
Subscribe To Our Newsletter & Stay Updated
